Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study.

infection (CDI) worsens inflammatory bowel disease (IBD) prognosis. While fecal microbiota transplantation (FMT) is effective for refractory or recurrent CDI (rrCDI), comparative success rates between IBD and non-IBD patients are scarce. This study addresses this gap. A retrospective cohort study was conducted at Chang Gung Memorial Hospital from April 2019 to October 2023. Patients receiving FMT for rrCDI were categorized into IBD and non-IBD groups. Baseline characteristics and outcomes were compared at one month and one year, with successful FMT defined as the resolution of diarrhea without CDI recurrence. The study included 88 patients: 30 with IBD and 58 without IBD. The IBD group was younger, with fewer comorbidities. Success rates at one month were similar between groups (IBD: 80.0% vs. non-IBD: 78.9%, = 0.908), as were negative toxin tests (IBD: 83.3% vs. non-IBD: 63.8%, = 0.174). One-year success rates (IBD: 70.0% vs. non-IBD: 67.6%, = 0.857) and eradication rates (IBD: 94.4% vs. non-IBD: 73.9%, = 0.112) were also similar. Poor bowel preparation predicted FMT failure at one month (OR = 0.23, = 0.019). No safety issues were reported. FMT is a safe, effective treatment for rrCDI, demonstrating similar success rates in patients with and without IBD.